In 1998, the American College of Gastroenterology issued ALIMENTARY TRACT
|
|
- Magdalene Mathews
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10: ALIMENTARY TRACT Effects of Dropping the Requirement for Goblet Cells From the Diagnosis of Barrett s Esophagus MARIA WESTERHOFF,* LINDSEY HOVAN, CHRISTINE LEE, and JOHN HART *Department of Anatomic Pathology, University of Washington Medical Center, Seattle, Washington; and Department of Pathology, University of Chicago Medical Center, Chicago, Illinois See editorial on page BACKGROUND & AIMS: The 2011 American Gastroenterological Association diagnostic criteria for Barrett s esophagus (BE) require the presence of goblet cells in biopsy specimens of columnar mucosa within the esophagus. In other countries, patients can be diagnosed with BE based on evidence of columnar epithelium, regardless of the presence of goblet cells. We examined the effects that a broader criteria would have on diagnoses of patients with endoscopically suspected BE. We also compared the clinical outcomes of patients with and without goblet cells in esophageal biopsy samples. METHODS: We analyzed the University of Chicago Medical Center database to identify 690 patients with no previous history of BE who underwent endoscopic biopsy analysis for BE from 1987 to We collected endoscopy reports, histology results, and chart reviews. RESULTS: Of biopsy specimens analyzed, samples from 258 patients contained goblet cells and 379 did not (53 of the biopsy samples contained only squamous mucosa). Patients whose biopsy samples contained goblet cells had longer endoscopic columnar segments (mean, 4.6 cm) and more biopsy specimens taken (mean, 5 biopsy specimens) than those without (mean length, 1.6 cm; mean, 4 biopsy specimens). Of patients whose biopsy specimens did not contain goblet cells, 35% underwent additional endoscopy; goblet cells continued to be absent in 88% of these (mean follow-up time, 5.8 y; 2.8 additional procedures; mean total biopsy specimens, 12). Goblet cells were identified in only 19% of all patients with columnar mucosa less than 2 cm. No patient without goblet cells developed adenocarcinoma. CONCLUSIONS: Decreasing the requirement for goblet cells would increase the diagnosis of BE by 147%. Among patients with short columnar segments, subsequent endoscopy generally does not reveal goblet cells, so the columnar mucosa might represent proximal stomach. Decreasing the requirement for goblet cells would cause many patients to be inaccurately labeled as BE. Keywords: Intestinal Metaplasia; Nongoblet Cell Mucosa; Esophageal Adenocarcinoma; Diagnostic and Prognostic Factors. In 1998, the American College of Gastroenterology issued practice guidelines for the diagnosis of Barrett s esophagus (BE). 1 In this document, Barrett s esophagus was defined by 2 criteria: (1) endoscopic evidence of a segment of columnar mucosa within the tubular esophagus, and (2) biopsy confirmation of intestinal metaplasia (goblet cells [GCs]) within the columnar segment. It was well known at that time that intestinal-type mucosa was not the only type of metaplastic columnar mucosa that could occur in Barrett s esophagus because gastric cardiac and fundic type of epithelium also had been documented in Barrett s segments. 2 However, intestinal metaplastic mucosa had been conventionally accepted as the only neoplastic precursor of esophageal adenocarcinoma. 3 5 The British Society of Gastroenterology subsequently published their criteria for the diagnosis of BE, and specifically omitted the requirement for biopsy confirmation of intestinaltype metaplasia (GCs). 6 Although the endoscopic requirements are similar to the previous American College of Gastroenterology guidelines, histologically, any type of columnar epithelium is regarded as acceptable to diagnose BE. They maintain that intestinal metaplasia can be missed by poor endoscopic sampling via inadequate numbers of biopsy specimens. Moreover, it is their contention that intestinal metaplasia always can be shown if enough biopsy specimens are taken over an adequate period of time. The controversy regarding the requirement for the presence of intestinal metaplasia has been addressed in the updated practice guidelines recently published by the American Gastrointestinal Association. 7 In this document, a distinction is made between the definition of BE and the criteria for the diagnosis of the condition. The definition of Barrett s has been broadened in the following manner, as follows:... the condition in which any extent of metaplastic columnar epithelium that predisposes to cancer development replaces the stratified squamous mucosa that normally lines the distal esophagus. 7 However, the guidelines go on to state that the diagnosis of BE currently requires biopsy confirmation of intestinal-type metaplastic epithelium because... intestinal metaplasia is the only type of esophageal columnar epithelium that clearly predisposes to malignancy. 7 This point is also a matter of debate because recent studies have contended that nonintestinal metaplastic Barrett s mucosa has the same cancer risk as that of intestinal type In the United States, broadening the criteria of BE to include all types of columnar mucosa would have a substantial impact Abbreviations used in this paper: BE, Barrett s esophagus; GC, goblet cell by the AGA Institute /$
2 November 2012 OVERDIAGNOSING BARRETT S ESOPHAGUS 1233 on medical costs and quality of life. The cost of life insurance for an otherwise healthy, nonsmoking man has been reported to have an average increase of 118% with a diagnosis of BE. 12 In a woman, this increase is averaged to be 177%. Most of such patients with BE live a normal life expectancy and die of causes other than esophageal adenocarcinoma. 13 A recent Dutch cohort study of more than 42,000 patients showed that the overall annual risk of cancer development was only 0.14%; low-grade dysplasia on initial endoscopic biopsy, older age, and male sex were the strongest predictors in progression to adenocarcinoma. 14 This retrospective analysis sought to determine how a broader histologic definition of BE would have affected the diagnosis of BE in patients with endoscopically identified columnar-lined mucosa. Second, we compared the neoplastic progression in these patients with and without GCs. Methods Patient information and tissue specimens were collected according to a protocol approved by the Institutional Review Board at the University of Chicago. Cases A search of a computerized pathology database for all adult patients between 1987 and 2008 identified 690 patients with the following specifications: (1) no previous diagnosis of BE (undergoing initial endoscopies), (2) endoscopically identified columnar-lined mucosa with clinical suspicion of BE (including 24 patients with irregular Z-lines), and (3) biopsy specimens obtained from the columnar-lined segment. Patients included 277 women and 413 men between the ages of 20 and 91 years. Pathology results and endoscopic information, including the length of the columnar segment and the number of biopsy specimens taken, were recorded. Chart review was performed on all patients to determine whether additional endoscopic procedures, esophagectomies, or mucosal resections were performed and for causes of death. Figure 1. Endoscopically measured length of columnar mucosa in the esophagus. Overall, the endoscopic length of columnar segments in patients with GCs were longer than in those without. The majority of patients without GCs had segments of only 1 or 2 cm in length. Table 1. Average Endoscopic Length and Number of Biopsy Specimens Taken Among Patients With and Without GC Patients with GC Patients without GC P value Average endoscopic length, cm Average number of biopsy specimens taken on initial endoscopy Statistics Statistical analysis was performed by using GraphPad Prism version 4.00 (GraphPad Software, San Diego CA) (2- tailed paired t tests) and Analyse-it for Microsoft Excel (version 2.20; Analyse-it Software, Ltd, ) (Mann Whitney U test and the Fisher exact probability test). Results Including Nongoblet Cells in the Definition of Barrett s Esophagus Would Have Increased the Initial Diagnosis by 147% A total of 258 patients had GCs identified in their initial endoscopic biopsy specimens. In contrast, 379 patients (who each also had a columnar-lined esophagus identified on endoscopy) had columnar mucosa devoid of GCs on biopsy. In these patients the biopsy specimens generally revealed gastric cardia type mucosa, although in some, oxyntic mucosa also was present. There were also 53 patients who did not show any evidence of columnar mucosa on biopsy. In these patients, biopsy specimens taken from what was reported to be columnar lining had only squamous epithelium present and this group was separated from further comparison. The lengths of the endoscopically identified columnar segments were longer in those with GC than those without (P.001; Figure 1, Table 1). The number of biopsy specimens taken on the initial endoscopy was higher for those with GCs, but the difference was not statistically significant (P.3; Figure 2, Table 1). Based on the American College of Gastroenterology guidelines, 37% (258 of 690) of all the patients with endoscopically visualized columnar mucosa were diagnosed with BE. However, using the British guidelines, 92% (637 of 690) of these patients would have been diagnosed with BE, increasing the diagnosis of Barrett s esophagus by 147%. Majority of Patients Without Goblet Cells Continue to Lack Them on Subsequent Endoscopies A total of 163 patients with GCs and 133 patients without GCs underwent at least 1 repeat endoscopic procedure at the University of Chicago Medical Center. Among those who did not have GCs on initial endoscopic biopsy specimens, 15 patients (12%) eventually had GCs upon repeat endoscopies (Table 2). However, the remaining 118 patients (88%) continued to lack GCs. There was no statistical difference between these 2 groups in regard to the number of additional endoscopic procedures (P.5) or the number of additional biopsy specimens taken (P.26). The mean follow-up period for the group
3 1234 WESTERHOFF ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 10, No. 11 Figure 2. Number of biopsy specimens taken on initial endoscopic biopsy. The number of biopsy specimens taken on initial endoscopy was generally higher for those who had intestinal metaplasia; they also had longer segments. These initial endoscopies were for diagnostic purposes and, hence, did not necessarily follow surveillance protocol for biopsies. without GCs was 5.8 years; for the group with GCs, the mean number of years followed up was 4.9 (P.5). The length of the endoscopic columnar segment was the only significant difference between these 2 groups (P.001). Overall, GCs were identified in only 19% of all patients with columnar segments less than 2 cm. Patients With Goblet Cell Mucosa Develop Dysplasia and Cancer Progression to dysplasia and cancer was compared in all patients with GCs (N 178) with those without GCs (N 118) over a range of 3 to 25 years (mean, 4.8 y in patients with GCs, and 5.8 y in those without GCs) (Figure 3). Dysplasia developed in 14 patients with GCs (Table 3). However, among the patients without GCs, none developed dysplasia or adenocarcinoma. Of the 15 patients who originally lacked GC on initial biopsy but had GC detected in a follow-up endoscopy, none developed dysplasia or adenocarcinoma. Two patients in whom GCs had been identified developed adenocarcinoma. One of these patients had high-grade dysplasia on a previous biopsy, and the other patient was discovered to have adenocarcinoma on an endoscopy after a period of 10 years lost to surveillance from the original procedure that had diagnosed BE. Overall, 78% (11 of 14) of the patients with dysplasia had endoscopic segments longer than 3 cm. The shortest segment with dysplasia was 2 cm. Thus, having short segment BE was Figure 3. Kaplan Meier curve for progression to dysplasia. There is a statistically significant difference between patients with GCs and patients without. not completely without risk because 22% (3 of 14) of those who developed dysplasia had segments less than 3 cm. Also, none of the patients described as having irregular Z lines developed dysplasia or cancer. The majority of patients who developed dysplasia or cancer were men (71% of those who developed dysplasia; 100% of those who developed cancer) and aged in their late 50s (mean age, 56.5 y). Among the patients with dysplasia, the average follow-up period was years. Of the patients with low-grade dysplasia, 63% regressed upon follow-up evaluation (5 of 8) and 37% remained the same grade (3 of 8). Of the patients with high-grade dysplasia, 17% progressed to cancer (1 of 6), 33% regressed (2 of 6), and 50% remained the same grade (3 of 6). There were 2 deaths among the group without GCs, but none were related to esophageal diseases. Among 3 deaths in the patients with GCs, one was related to esophageal cancer, but was secondary to the esophagectomy and not the tumor itself. Also, separate from the rest of this study, there were 10 patients with prevalent dysplasia and 2 patients with cancer discovered on initial endoscopy. All of these patients had endoscopic columnar segments longer than 3 cm (average, 6.2 cm) and had GCs present in their biopsy specimens. Discussion This study addressed the potential impact of broadening the criteria of BE. Our findings show that broadening the criteria of BE by decreasing the requirement for GCs increases the percentage of patients who would have been labeled as having BE from 37% to 92%. However, based on both chart Table 2. The Average Number of Additional Procedures and Biopsy Specimens Taken in Patients With No GCs on Initial Biopsy, Who Underwent Subsequent Endoscopy No GCs on subsequent biopsy specimens (n 118) GCs identified on subsequent biopsy specimens (n 15) P value Average number of additional endoscopic procedures Average number of additional biopsies Average years of follow-up evaluation Average endoscopic length of columnar mucosa, cm NOTE. There were 133 patients with no GCs on initial biopsy specimens who underwent follow-up endoscopy.
4 November 2012 OVERDIAGNOSING BARRETT S ESOPHAGUS 1235 Table 3. Neoplastic Outcome of Patients With No GCs vs All Patients With GCs No GCs (n 118) GCs (n 178) P value Average number of additional endoscopic procedures Average years of follow-up evaluation Progression to dysplasia, n Progression to adenocarcinoma, n review and follow-up endoscopy, the patients lacking GCs did not develop dysplasia or esophageal adenocarcinoma. There are several possible explanations for the group of patients with endoscopic and histologic columnar mucosa but without intestinal metaplasia. First, the columnar mucosa lacking GCs could represent proximal gastric mucosa because it is possible that endoscopists occasionally mistake gastric cardia as a segment of BE. In our study, only 19% of all patients with segments less than 2 cm had GCs. In one study, 84 trained endoscopists evaluated a set of 30 endoscopic cases and were asked to locate where the esophagus ended. 15 By using a Japanese endoscopic criteria where the distal end of the esophageal vessels demarcates where the esophagus ends, an interobserver value of only 0.17 was achieved, whereas by using the Prague criteria an interobserver value of 0.35 was observed. This study illustrates the difficulty in accurately identifying the esophagogastric junction endoscopically in patients with possible short-segment Barrett s esophagus. In such cases, decreasing the requirement for GCs from the definition of BE may erroneously increase the diagnosis based on biopsy specimens of columnar mucosa from the proximal stomach. The second possibility is that the group without GCs may represent poor sampling during endoscopy. In our study, 12% of the patients who originally lacked GCs were found to have them on subsequent endoscopy. These patients either had GCs initially that were missed by poor sampling the first time around, or developed GCs during the course between repeat endoscopies. However, in contrast to the British Society of Gastroenterology, which reasons that intestinal metaplasia always can be shown in patients with esophageal columnar mucosa over time, 88% of our patients without GCs continued to lack them subsequently. They had comparable numbers of endoscopic procedures, numbers of biopsy specimens, and years of follow-up evaluation as the group with GCs. These results are similar to the findings of data from an Irish population that concluded that GCs seem to either be present from the start or absent. 16 Finally, the columnar mucosa in the patients lacking GCs may represent metaplastic mucosa without intestinal metaplasia that is reported to harbor precancerous abnormalities. 11,17 Although a recent study has shown DNA content abnormalities from biopsy specimens of non-gc columnar mucosa in patients with irregular Z-lines, none of the patients in our study with irregular Z-lines developed dysplasia or cancer. 11 This raises the question of whether abnormalities in DNA content are clinically significant in nondysplastic mucosa that likely is chronically inflamed. Our finding of an absence of risk for dysplasia or cancer in patients without GCs is in agreement with the previously mentioned Irish data (2969 patients), in which the risk of esophageal adenocarcinoma in patients with non-gc mucosa was found to be similar to that of the general population. 16 Our findings are, on the other hand, in direct contrast to reports from the United Kingdom, which concluded that there is no difference in cancer development among patients with or without GCs. 10 These studies, however, were based largely on chart review, whereas our report also analyzed biopsy specimens from follow-up endoscopies. For example, the article by Kelty et al 10 categorized their patients into those with and without GCs by reviewing index biopsy specimens, of which there was an average of only 4. They excluded cases of patients who had undergone follow-up endoscopies with further biopsies. There was also no mention of endoscopic segment length. They then followed up patients outcomes by chart review and cancer registry data. It is possible that their results may be based on poor sampling and that the adenocarcinoma that developed from patients without GCs were in fact reflective of poor sampling. In summary, this study of American patient data analyzed the neoplastic outcome of patients with and without GC. It also quantifies the marked increase in the diagnosis of BE that would occur if the broader criteria for BE was adopted. An alternative approach would be to target patients who are at highest risk of cancer development, such as dysplasia on initial endoscopic biopsy, male sex, and older age, which may aid in protocols for endoscopic surveillance. References 1. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93: Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett s esophagus. N Engl J Med 1976;295: Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett s mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002;16: Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus 2007;20: Krishnadath KK. Novel findings in the pathogenesis of esophageal columnar metaplasia or Barrett s esophagus. Curr Opin Gastroenterol 2007;23: Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett s oesophagus. Gut 2006;55: American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett s esophagus. Gastroenterology 2011;140: Chaves P, Crespo M, Ribeiro C, et al. Chromosomal analysis of Barrett s cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol 2007;20: Gatenby PA, Ramus JR, Caygill CP, et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol 2008;43: Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007;42: Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities
5 1236 WESTERHOFF ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 10, No. 11 similar to goblet cell-containing epithelium. Am J Gastroenterol 2009;104: Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett s esophagus on insurance status. Am J Gastroenterol 2005;100: Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8: ; quiz, e de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett s oesophagus: a Dutch nationwide cohort study. Gut 2010;59: Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006;64: Murphy SJ, Johnston BT, Murray LJ. British Society of Gastroenterology guidelines for the diagnosis of Barrett s oesophagus: are we casting the net too wide? Gut 2006;55: Riddell RH, Odze RD. Definition of Barrett s esophagus: time for a rethink is intestinal metaplasia dead? Am J Gastroenterol 2009;104: Reprint requests Address requests for reprints to: Maria Westerhoff, MD, 1959 NE Pacific Street, Seattle, Washington fax: (206) mariawesterhoff@gmail.com Conflicts of interest The authors disclose no conflicts. Funding Supported by the University of Chicago Department of Pathology.
Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful in characterizing esophageal location
Diseases of the Esophagus (2005) 18, 87 92 2005 ISDE Blackwell Publishing, Ltd. Original article Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful
More informationBarrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationIs intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?
Diseases of the Esophagus (2007) 20, 36 41 DOI: 10.1111/j.1442-2050.2007.00638.x Blackwell Publishing Asia Original article Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of
More informationThe presence of intestinal-type goblet cells (ITGCs) in
Goblet Cell Mimickers in Esophageal Biopsies Are Not Associated With an Increased Risk for Dysplasia Mamoun Younes, MD; Atilla Ertan, MD; Gulchin Ergun, MD; Ray Verm, MD; Margaret Bridges, MD; Karen Woods,
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationCurrent Management: Role of Radiofrequency Ablation
Esophageal Adenocarcinoma And Barrett s Esophagus: Current Management: Role of Radiofrequency Ablation Ketan Kulkarni, MD Regional Gastroenterology Associates of Lancaster INTRODUCTION The prognosis of
More informationBarrett s esophagus. Barrett s neoplasia treatment trends
Options for endoscopic treatment of Barrett s esophagus Patrick S. Yachimski, MD MPH Director of Pancreatobiliary Endoscopy Assistant Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationSAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #
SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST Ver. #5-02.12.17 GUIDELINES FOR DEVELOPING SELF-ASSESSMENT MODULES TEST The USCAP is accredited by the American Board of Pathology (ABP) to offer
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationBarrett esophagus. Bible class Inselspital
Barrett esophagus Bible class Inselspital 2015.08.10 Guidelines Definition? BSG: ACG: Definition? BSG: ACG: What are the arguments for and against IM as prerequisite for the Dg? What are the arguments
More informationAdenocarcinoma of the distal esophagus is a recognized
ORIGINAL ARTICLE Adenocarcinomas of the Distal Esophagus and Gastric Cardia Are Predominantly Esophageal Carcinomas Parakrama Chandrasoma, MD, Kumari Wickramasinghe, MD, PhD, Yanling Ma, MD, and Tom DeMeester,
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationRelative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia
Gut 2000;46:9 13 9 PAPERS Division of Gastroenterology, University of Kansas, VA Medical Center, Kansas City, Missouri, USA P Sharma A P Weston Department of Pathology, VA Medical Center, Kansas M Topalovski
More informationVital staining and Barrett s esophagus
Marcia Irene Canto, MD, MHS Baltimore, Maryland Vital staining or chromoendoscopy refers to staining of endoscopic tissue or topical application of chemical stains or pigments to alter tissue appearances
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationHenry Moon was one of the giants in academic pathology during my early years.
Henry Moon was one of the giants in academic pathology during my early years. Controversial stuff that occurs slightly above, within or slightly below the gastroesophageal junction, including Barrett s
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationThis medical position statement considers a series of
GASTROENTEROLOGY 2011;140:1084 1091 American Gastroenterological Association Medical Position Statement on the Management of Barrett s Esophagus The Institute Medical Position Panel consisted of the authors
More informationOne of the more common specimens encountered by
Controversies in the Diagnosis of Barrett Esophagus and Barrett-Related Dysplasia One Pathologist s Perspective John R. Goldblum, MD N Context. Pathologists frequently assess esophageal biopsy specimens
More informationAccepted Manuscript. CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D
Accepted Manuscript CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D PII: S1542-3565(18)31093-0 DOI: 10.1016/j.cgh.2018.10.010 Reference: YJCGH 56132
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationLearning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationAmerican Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma
Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma Journal: Manuscript ID: AJG-13-1412.R1 Manuscript Type: Letter to the Editor Keywords: Barrett-s esophagus, Esophagus, Endoscopy
More informationA bs tr ac t. n engl j med 365;15 nejm.org october 13,
The new england journal of medicine established in 1812 october 13, 2011 vol. 365 no. 15 Incidence of Adenocarcinoma among Patients with Barrett s Esophagus Frederik Hvid-Jensen, M.D., Lars Pedersen, Ph.D.,
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationBarrett s Esophagus in Women: Demographic Features and Progression to High-Grade Dysplasia and Cancer
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1089 1094 Barrett s Esophagus in Women: Demographic Features and Progression to High-Grade Dysplasia and Cancer GARY W. FALK,* PRASHANTHI N. THOTA,* JOEL
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationOriginal article INTRODUCTION
Diseases of the Esophagus (2014), DOI: 10.1111/dote.12166 Original article A Barrett s esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based
More informationTHE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 97, No. 1, by Am. Coll. of Gastroenterology ISSN /02/$22.00
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 97, No. 1, 2002 2002 by Am. Coll. of Gastroenterology ISSN 0002-9270/02/$22.00 Published by Elsevier Science Inc. PII S0002-9270(01)03982-X ORIGINAL CONTRIBUTIONS
More informationPatterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus Robert J. Korst, MD, a,b Sobeida Santana-Joseph, MSN, a,b John R. Rutledge, MAS,
More informationTobacco Smoking Increases the Risk of High-Grade Dysplasia and Cancer Among Patients With Barrett s Esophagus
GASTROENTEROLOGY 2012;142:233 240 CLINCAL ALIMENTARY TRACT Tobacco Smoking Increases the Risk of High-Grade Dysplasia and Cancer Among Patients With Barrett s Esophagus HELEN G. COLEMAN,* SHIVARAM BHAT,*
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationIdentification of gastric atrophic changes: from histopathology to endoscopy
Evidence in perspective 533 Identification of gastric atrophic changes: from histopathology to endoscopy Authors Mário Dinis-Ribeiro 1,2, Ernst J. Kuipers 3 Institutions Bibliography DOI http://dx.doi.org/
More informationSAM PROVIDER TOOLKIT
THE AMERICAN BOARD OF PATHOLOGY Maintenance of Certification (MOC) Program SAM PROVIDER TOOLKIT Developing Self-Assessment Modules (SAMs) www.abpath.org The American Board of Pathology (ABP) approves educational
More informationSixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation
Original Article Sixteen-year of Barrett s esophagus, endoscopically treated with argon plasma coagulation United European Gastroenterology Journal 2014, Vol. 2(5) 367 373! Author(s) 2014 Reprints and
More informationBarrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions
Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions Robert Odze, MD, FRCPC Chief, Gastrointestinal Pathology Associate Professor of Pathology Brigham and Women s Hospital Harvard
More informationThe increasing incidence of esophageal adenocarcinoma
GASTROENTEROLOGY 2004;127:310 330 A Critical Review of the Diagnosis and Management of Barrett s Esophagus: The AGA Chicago Workshop PRATEEK SHARMA,* KENNETH MCQUAID, JOHN DENT, M. BRIAN FENNERTY, RICHARD
More informationCircular stripes were more common in Barrett s esophagus after acetic acid staining
Sun et al. BMC Gastroenterology (2018) 18:17 DOI 10.1186/s12876-018-0745-7 RESEARCH ARTICLE Open Access Circular stripes were more common in Barrett s esophagus after acetic acid staining Yating Sun 1,
More informationBarrett esophagus is a premalignant condition resulting
Diagnostic Challenges in the Pathologic Evaluation of Barrett Esophagus Rhonda K. Yantiss, MD N Context. Barrett esophagus represents an unstable epithelium resulting from chronic gastroesophageal reflux
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationRADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS
DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus. Original Policy Date
MP 2.01.52 Endoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationAdenocarcinoma of the Esophagogastric Junction and Barrett's Esophagus
GASTROENTEROLOGY 1995;109:1541-1546 Adenocarcinoma of the Esophagogastric Junction and Barrett's Esophagus ALAN J. CAMERON,* CLIFFORD T. LOMBOY,* MANUEL PERA,* and HERSCHEL A. CARPENTER g *Division of
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationIntestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease?
Gut 1998;43:17 21 17 Gastroenterology, Hepatology, and Infectious Diseases A Hackelsberger V Schultze G Manes J-E Dominguez-Muñoz P Malfertheiner Pathology, Otto-von-Guericke University, Magdeburg, Germany
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationFrequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease
Original Article Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease From Military Hospital, Rawalpindi Obaid Ullah Khan, Abdul Rasheed Correspondence: Dr. Abdul
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationORIGINAL ARTICLE. Adenocarcinoma of the Esophagus With and Without Barrett Mucosa
ORIGINAL ARTICLE Adenocarcinoma of the Esophagus With and Without Barrett Mucosa Michael S. Sabel, MD; Kate Pastore, MD; Hannah Toon, MD; Judy L. Smith, MD Hypothesis: Previous studies have demonstrated
More informationOpinion Statement. Esophagus (E Dellon, Section Editor)
Curr Treat Options Gastro (2016) 14:1 18 DOI 10.1007/s11938-016-0080-4 Esophagus (E Dellon, Section Editor) Current Controversies in Radiofrequency Ablation Therapy for Barrett s Esophagus Kamar Belghazi,
More informationAdherence to Surveillance Guidelines in Nondysplastic Barrett s Esophagus.
Adherence to Surveillance Guidelines in Nondysplastic Barrett s Esophagus. Kunal S. Dalal, MD 1 ; Jessica Coffing, MPH 2 ; Thomas F. Imperiale, MD 1 Affiliations: 1 Indiana University School of Medicine,
More informationThe incidence of esophageal adenocarcinoma is rising in the ENDOSCOPY CORNER
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:843 847 ENDOSCOPY CORNER Acetic Acid Spray Is an Effective Tool for the Endoscopic Detection of Neoplasia in Patients With Barrett s Esophagus GAIUS LONGCROFT
More informationParis classification (2003) 삼성의료원내과이준행
Paris classification (2003) 삼성의료원내과이준행 JGCA classification - Japanese Gastric Cancer Association - Type 0 superficial polypoid, flat/depressed, or excavated tumors Type 1 polypoid carcinomas, usually attached
More informationThe normal esophagus is lined with squamous epithelium.
.. ALAN J. CAMERON, M.D. In Barrett's esophagus, the squamous lining of the lower esophagus is replaced by columnar epithelium. Barrett's esophagus is associated with gastroesophageal reflux and an increased
More informationThe esophagogastric junction (EGJ), the region between
Review Article Definition of the Esophagogastric Junction A Critical Mini Review Qin Huang, MD, PhD N Context. Accurate diagnosis of diseases involving the esophagogastric junction (EGJ) is challenging
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationWhat s New in the Management of Esophageal Disease
What s New in the Management of Esophageal Disease Philip O. Katz, MD Chairman, Division of Gastroenterology Einstein Medical Center Philadelphia Clinical Professor of Medicine Jefferson Medical College
More informationHistological Features of Gastric Cardia in Adults: an Autopsy
original PAPERs Histological Features of Gastric Cardia in Adults: an Autopsy Study Zorica M. Stojsic 1, Radmila M. Stevanovic 1, Martina M. Stojanovic 1, Aleksandar D. Stanojevic 2, Dragoljub T. Bacetic
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationVolumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus
E318 Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment esophagus Authors Institution Arvind J. Trindade, Benley J. George, Joshua Berkowitz,
More informationIt has been estimated that 5.6% of adults in the United States have
The new england journal of medicine review article Dan L. Longo, M.D., Editor Barrett s Esophagus Stuart J. Spechler, M.D., and Rhonda F. Souza, M.D. From the Esophageal Diseases Center, Department of
More informationDisclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease
Kunal Jajoo, MD Brigham and Women s Hospital July 2012 Disclosures Spouse is a physician employed by Boston Scientific Corporation The content of this lecture equitably discusses products of multiple companies
More informationOesophagus and Stomach update dysplasia and early cancer
Oesophagus and Stomach update dysplasia and early cancer Dr Tim Bracey STR teaching 13/4/16 Please check pathkids.com for previous talks One of the biggest units in the country (100 major resections per
More informationSection: Medicine Effective Date: July 15, 2015 Subsection: Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: June 2015 Page: 1 of 16 Cryoablation for Barrett s Esophagus Description Barrett s esophagus (BE) is a condition in which the normal squamous epithelium is replaced by specialized
More informationIntroduction. Original articles. Nicolás Rocha, 1 Sandra Huertas, 2 Rosario Albis, 3 Diego Aponte, 4 Luis Carlos Sabbagh. 5
Original articles Correlation of endoscopic and histological findings in diagnosis of gastrointestinal metaplasia in patients referred to the Clinica Colombia for upper endoscopies Nicolás Rocha, 1 Sandra
More informationEvaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia
...PRESENTATIONS... Evaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia Based on a presentation by Bergein F. Overholt, MD Presentation Summary Thermal ablation and surgery are
More informationDivision of Anatomic Pathology & Molecular Oncology, University of Utah and ARUP Laboratories, Huntsman Cancer Institute, Salt Lake City, UT, USA
REVIEW ISSN 1738-3331, http://dx.doi.org/10.7704/kjhugr.2014.14.3.131 The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2014;14(3):131-162 Barrett s Esophagus Mary P. Bronner Division
More informationOesophageal signet ring cell carcinoma as complication of gastro-oesophageal reflux disease
Alimentary Pharmacology and Therapeutics Oesophageal ring cell carcinoma as complication of gastro-oesophageal reflux disease K. O. Turner*,, R. M. Genta*,, & A. Sonnenberg, *Miraca Life Sciences Research
More informationChapter 12: Training in Pathology. DDSEP Chapter 13: Question 19
DDSEP Chapter 13: Question 19 A 70 year-old male with a history of celiac disease diagnosed in his forties reports abdominal pain, dark stools, and 20-pound weight loss. He reports complete compliance
More informationTHE USE OF SPECIAL STAINS IN THE DIAGNOSIS OF BARRETT ESOPHAGUS AND BARRETT DYSPLASIA: RECOMMENDATIONS FROM THE RODGER C. HAGGITT GASTROINTESTINAL
THE USE OF SPECIAL STAINS IN THE DIAGNOSIS OF BARRETT ESOPHAGUS AND BARRETT DYSPLASIA: RECOMMENDATIONS FROM THE RODGER C. HAGGITT GASTROINTESTINAL PATHOLOGY SOCIETY Amitabh Srivastava 1, Henry Appelman
More informationProton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett s Esophagus
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2004.30228.x Published by Blackwell Publishing ORIGINAL CONTRIBUTIONS Proton Pump Inhibitors
More informationScreening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France
Screening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France Barrett s esophagus (BE) is an acquired condition in which the normal squamous epithelium
More informationIdentifying Intestinal Metaplasia at the Squamocolumnar Junction by Using Optical Coherence Tomography
Identifying Intestinal Metaplasia at the Squamocolumnar Junction by Using Optical Coherence Tomography The Harvard community has made this article openly available. Please share how this access benefits
More informationAchalasia is a rare disease with an annual incidence estimated REVIEWS. Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:1020 1024 REVIEWS Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia BOUDEWIJN F. KESSING, ALBERT J. BREDENOORD, and ANDRÉ J. P. M. SMOUT
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy Authors: Dr Stephen Hayes, Dr David Bisset, Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments
More informationHow to characterize dysplastic lesions in IBD?
How to characterize dysplastic lesions in IBD? Name: Institution: Helmut Neumann, MD, PhD, FASGE University Medical Center Mainz What do we know? Patients with IBD carry an increased risk of developing
More informationBurning Issues in the Esophagus
Burning Issues in the Esophagus Elizabeth Montgomery, MD Johns Hopkins Medical Institutions Dr. Montgomery reports no relevant financial relationships with commercial interests. Squamous Epithelium Muscularis
More informationChapter 2 Complications of Gastroesophageal Reflux Disease
Chapter 2 Complications of Gastroesophageal Reflux Disease Patrick Yachimski Acute esophageal exposure to gastric and/or duodenal refluxate can result in pyrosis and symptomatic gastroesophageal reflux
More informationBarrett s esophagus (BE) is a precancerous state
CLINICAL ALIMENTARY TRACT Gastroenterology 2017;153:681 688 Late Recurrence of Barrett s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
30 PRACTICE GUIDELINES nature publishing group CME ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G.
More informationBarrett s esophagus: lessons from recent clinical trials
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-7 Barrett s esophagus: lessons from recent clinical trials Daniela Golger, Andreas Probst, Helmut Messmann Klinikum Augsburg, Germany Abstract Data
More informationMagnifying Endoscopy and Chromoendoscopy of the Upper Gastrointestinal Tract
Magnifying Endoscopy and Chromoendoscopy of the Upper Gastrointestinal Tract Alina M.Boeriu 1, Daniela E.Dobru 1, Simona Mocan 2 1) Department of Gastroenterology, University of Medicine and Pharmacy;
More informationEndoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell
Endoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell Department of Internal Medicine 2, HSK Wiesbaden, Wiesbaden, Germany Correspondence to Oliver Pech, MD, PhD, Department of Gastroenterology,
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationStudy on prevalence of neoplastic lesions of the esophagus in patients referred to health centers of Ahvaz in the years
Available online at www.ijmrhs.com ISSN No: 29-5886 International Journal of Medical Research & Health Sciences, 26, 5, :5-54 Study on prevalence of neoplastic lesions of the esophagus in patients referred
More informationBarrett s Esophagus: State of the Art Management
In the Name of God Barrett s Esophagus: State of the Art Management Siavosh Nasseri-Moghaddam MD, MPH, AGAF Associate Professor of Medicine Digestive Disease Research Center, Shariati Hospital, TUMS IAGH
More informationChromoendoscopy and Endomicroscopy for detecting colonic dysplasia
Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia Ralf Kiesslich I. Medical Department Johannes Gutenberg University Mainz, Germany Cumulative cancer risk in ulcerative colitis 0.5-1.0%
More informationNewly developed magnifying endoscopic classification of the Japan Esophageal Society to identify superficial Barrett s esophagus related neoplasms
https://doi.org/10.1007/s10388-018-0623-y SPECIAL ARTICLE Newly developed magnifying endoscopic classification of the Japan Esophageal Society to identify superficial Barrett s esophagus related neoplasms
More informationCLINICAL EFFECTIVENESS
Re-audit of gastrointestinal tract specimens with respect to compliance with RCPath guidelines Dr Manisha Ram Dr Moina Kadri Background epidemiology and aetiology Over the past 20 years there has been
More informationLarge Colorectal Adenomas An Approach to Pathologic Evaluation
Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationFrom reflux to esophageal cancer. Josh Boys, MD TCV 2 nd year indentured servant
From reflux to esophageal cancer Josh Boys, MD TCV 2 nd year indentured servant The Pathway Esophageal Squamous epithelium+reflux Columnar lined esophagus (CLE) or Cardiac mucosa Intestinal Metaplasia
More information